Pliant Net Income From Continuing Ops from 2010 to 2026
| PLRX Stock | USD 1.17 0.03 2.63% |
Net Loss | First Reported 2019-03-31 | Previous Quarter -43.3 M | Current Value -26.3 M | Quarterly Volatility 21.1 M |
Check Pliant Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pliant Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.7 M, Interest Expense of 3.7 M or Selling General Administrative of 71.3 M, as well as many indicators such as Price To Sales Ratio of 636, Dividend Yield of 0.0 or PTB Ratio of 2.48. Pliant financial statements analysis is a perfect complement when working with Pliant Therapeutics Valuation or Volatility modules.
Pliant | Net Income From Continuing Ops | Build AI portfolio with Pliant Stock |
The evolution of Net Income From Continuing Ops for Pliant Therapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Pliant Therapeutics compares to historical norms and industry peers.
Latest Pliant Therapeutics' Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Pliant Therapeutics over the last few years. It is Pliant Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pliant Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Pliant Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (74,700,384) | |
| Coefficient Of Variation | (92.43) | |
| Mean Deviation | 59,653,673 | |
| Median | (30,276,000) | |
| Standard Deviation | 69,046,496 | |
| Sample Variance | 4767.4T | |
| Range | 209.7M | |
| R-Value | (0.82) | |
| Mean Square Error | 1657T | |
| R-Squared | 0.67 | |
| Significance | 0.000053 | |
| Slope | (11,226,685) | |
| Total Sum of Squares | 76278.7T |
Pliant Net Income From Continuing Ops History
About Pliant Therapeutics Financial Statements
Pliant Therapeutics investors use historical fundamental indicators, such as Pliant Therapeutics' Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Pliant Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Loss | -189.3 M | -179.8 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Pliant Stock Analysis
When running Pliant Therapeutics' price analysis, check to measure Pliant Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pliant Therapeutics is operating at the current time. Most of Pliant Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pliant Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pliant Therapeutics' price. Additionally, you may evaluate how the addition of Pliant Therapeutics to your portfolios can decrease your overall portfolio volatility.